Harris Jaryse C, Schubert Jeffrey, Lockhart Brian, Olson Rachel, Paessler Michele E, Margolskee Elizabeth, Pillai Vinodh, Wu Jinhua, Golenberg Netta, Chen Jiani, Denenberg Elizabeth H, Luke Tammy, Luo Minjie, Zhong Yiming, Li Marilyn M, Wertheim Gerald B
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Division of Genomic Diagnostics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Pediatr Dev Pathol. 2025 May-Jun;28(3):214-219. doi: 10.1177/10935266251316150. Epub 2025 Feb 3.
We report a case of acute myeloid leukemia with megakaryoblastic differentiation (AMKL) that developed after an initial B-lymphoblastic leukemia (B-ALL) with low hypodiploidy. Although the AMKL was initially thought either to be a phenotypic change from the original B-ALL or to have arisen as a result of treatment (acute myeloid leukemia, post cytotoxic therapy, AML-pCT [WHO]; AML, therapy related [ICC]), genetic evaluation of both the AMKL and the B-ALL suggest that neither of these considerations was correct. Rather, the AMKL did not harbor the most common genetic hallmark of AML-pCT-rearrangement of and was genetically distinct from the B-ALL. Both the B-ALL and the AMKL, however, showed an identical mutation by next generation sequencing (NGS), while germline testing was negative for this mutant allele. Hence, either the patient had a tissue restricted constitutional mutation or had a somatic mutation in a multipotent hematopoietic precursor. This case highlights the necessity for close monitoring of patients with -mutant tumors, as they may develop multiple lesions despite negative germline testing.
我们报告了一例急性巨核细胞白血病分化型(AMKL),其发生于最初的低二倍体B淋巴细胞白血病(B-ALL)之后。尽管最初认为AMKL要么是原始B-ALL的表型改变,要么是治疗的结果(急性髓系白血病,细胞毒性治疗后,AML-pCT [世界卫生组织];AML,治疗相关 [国际癌症研究机构]),但对AMKL和B-ALL的基因评估表明这两种情况都不正确。相反,AMKL没有AML-pCT最常见的基因特征—— 重排,并且在基因上与B-ALL不同。然而,通过下一代测序(NGS),B-ALL和AMKL都显示出相同的 突变,而种系检测该突变等位基因为阴性。因此,要么患者有组织限制性的 基因构成突变,要么在多能造血前体中有体细胞突变。该病例强调了对 突变肿瘤患者进行密切监测的必要性,因为尽管种系检测为阴性,他们仍可能发生多种病变。